Our History - BMYscreen
wait
ABOUT US
OUR HISTORY
BMYscreen was created in 2014 as a spin off from the Chevet laboratory, INSERM/University of Bordeaux, with the support of the « Conseil Régional D’Aquitaine », the SIRIC BRIO and the Cancéropôle Grand Sud-Ouest.
At its origin in 2007, our infrastructure was set up as a technological platform relying on Alphascreen® for exclusive use in the laboratory and dedicated to basic and translational research projects. In 2010, we developed several new assays and undertook our first screening to search for bioactive small molecules. In the course of the following years, external collaborations and solicitations from national and international partners led us to contribute our expertise to many projects aiming at :
Characterizing protein-protein interactions (PPis; refs 1, 2, 3, 4, 5, 6)
Characterizing protein-nucleic acids interactions (PNis; refs 7, 8)
Measuring enzymatic activities (refs 5, 9)
Quantifying the activation of selected signaling pathways (refs 9, 10, 11)
Quantifying serum biomarkers (ref 3)
To cope with this increasing demand, in 2013 BMYscreen was officially identified as an Inserm platform and in January 2014 granted with the label “Cellule de Transfert” by the Conseil Régional d’Aquitaine, with the management of ADERA (Association pour le Développement de l’Enseignement et des Recherches auprès des universités, des centres de Recherche et des entreprises d’Aquitaine). From this time, new technological development took place within BMYscreen with the implementation of the Cytation 3 (BioTek) and the development of reporter system in live cells to monitor molecular stresses.
Today BMYscreen activity development is supported by the SIRIC BRIO and the Cancéropôle Grand Sud-Ouest and benefits from tight partnerships with PerkinElmer and Bioscale Inc.
 
Publications (2009 - present)
1) Taouji S, Dahan S, Bossé R, Chevet E. Current Screens Based on the AlphaScreen Technology for Deciphering Cell Signalling Pathways. Curr Genomics. 2009 Apr;10(2):93-101.
2) Bouchecareilh M, Caruso ME, Roby P, Parent S, Rouleau N, Taouji S, Pluquet O, Bossé R, Moenner M, Chevet E. AlphaScreen-based characterization of the bifunctional kinase/RNase IRE1alpha: a novel and atypical drug target. J Biomol Screen. 2010 Apr;15(4):406-17.
3) Mazella J, Pétrault O, Lucas G, Deval E, Béraud-Dufour S, Gandin C, El-Yacoubi M, Widmann C, Guyon A, Chevet E, Taouji S, Conductier G, Corinus A, Coppola T, Gobbi G, Nahon JL, Heurteaux C, Borsotto M. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010 Apr 13;8(4):e1000355.
4) Bouchecareilh M, Higa A, Fribourg S, Moenner M, Chevet E. IRE1alpha kinase-derived active peptides modulate IRE1alpha activity and protect cells from Endoplasmic Reticulum stress. FASEB Journal, 2011 Sep;25(9):3115-29.
5) Platonova N, Miquel G, Regenfuss B, Taouji S, Cursiefen C, Chevet E, Bikfalvi A. Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. Blood. 2013 Feb 14;121(7):1229-37.
6) Bernard SC, Simpson N, Join-Lambert O, Federici C, Laran-Chich MP, Maïssa N, Bouzinba-Ségard H, Morand PC, Chretien F, Taouji S, Chevet E, Janel S, Lafont F, Coureuil M, Segura A, Niedergang F, Marullo S, Couraud PO, Nassif X, Bourdoulous S. Pathogenic Neisseria meningitidis utilizes CD147 for vascular colonization. Nat Med. 2014 Jul;20(7):725-31.
7) Dausse E, Taouji S, Evade L, Di Primo C, Chevet E*, Toulme JJ*. HAPIscreen, a method for high-throughput aptamer identification. J Nanobiotechnology. 2011 Jun 3;9(1):25. *corresponding authors.
8) Taouji S, Dausse E, Evadé L, Di Primo C, Toulmé JJ, Chevet E. Advances in binder identification and characterisation: the case of oligonucleotide aptamers. N Biotechnol. 2012 Jun 15;29(5):550-4.
9) Bideaud-Meynard A, Arma D, Taouji S, Laguerre M, Dessolin J, Rosenbaum J, Chevet E*, Moreau V*. A novel small-molecule screening strategy identifies mitoxantrone as a RhoGTPase inhibitor. Biochem J., 2013 Feb 15;450(1):55-62. *corresponding authors.
10) Taouji S, Higa A, Delom F, Palcy S, Mahon FX, Pasquet JM, Bosse R, Segui B, Chevet E. Phosphorylation of Serine Palmitoyl Transferase Long Chain-1 (SPTLC1) on Tyrosine 164 inhibits its activity and promotes cell survival. J Biol Chem. 2013 Jun 14;288(24):17190-201.
11) Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G, Mallet M, Taouji S, Balabaud C, Terris B, Canal F, Paradis V, Scoazec JY, de Muret A, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-Rossi J. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014 Apr 14;25(4):428-41.
 
Close
Loading...
Wait
Please wait
Loading longer than expected.
Wait 30 more seconds   Reload